1. STS Presentation

2. Executive Summary Huge market with high growth potential through right therapeutics areas focus  2 nd highest population in middle east after Egypt, 18 th in the world and ranked 94 th in growth rate worldwide  Iran is the 3 rd biggest Pharma market in the middle east after KSA and turkey  Political situation and sanctions is expected to be lifted in early 2016.  Reimbursement covers 83% of the population with co-pay of 30% to medicines.  Pharmaceutical market growing at a CAGR of 18% by value in € during 2009 till 2012 and Iran is ranked 3 rd pharmaceutical sales in meta region after turkey and KSA with $3.20 Bn in 2014.  Market growth is expected to continue but in slower rate ( approx. 12% to 15% till 2020).  Imported products contribute to 3% by volume and 37% by value while top 10 products by value are all specialty products and they contribute to 8% of the market. I.E. New launched products in diabetes, cancer., Etc.  The use of locally produced generics is widespread, especially in the governmental sector where Iran is mainly a generics market but with high brand loyalty among specialists and people.  Foreign players are enhanced to get to licensing agreements with local manufacturers since government & MOH support local production.  Successful MNCS are adopting different import and a focused therapeutic area strategy with localization as an important arm to allow registration and better pricing with a lesser custom tariff

3. Macroeconomics & sociopolitical situation  POPULATION (MIN) (2015 EST.) 84  POPULATION GROWTH RATE (2015 EST.) 1.24  BIRTH RATE / 1,000 POPULATION (2015 EST.) 1.5K  DEATH RATE / 1,000 POPULATION (2015 EST.) 400K  URBAN POPULATION 71%  LIFE EXPECTANCY YEARS 75  SINGLE MOTHERS FAMILY 9.5%  OIL EXPORT / MILLION BARREL / DAY 2.2  GDP PER CAPITA ($)(2014) 4751  INFLATION RATE (CONSUMER PRICES) 24%  LITERATURE RATE 85%  UNEMPLOYMENT RATE(2015) 19%  HEALTHCARE EXPENDITURE AS % OH GDP 7.8%  GOVERNMENT HEALTHCARE EXPENDITURE, US BN.(2014) 11.3  PRIVATE HEALTHCARE EXPENDITURE,US BN.(2014) 20  NUMBER OF PHYSICIANS /1000 POPULATION 0.89  NUMBER OF HOSPITALS BEDS / 1000 POPULATION 1.7

5. Potential market http://avab.behdasht.gov.ir/hospital / Hospital TypeNumber % Educational University22 Medical University41 Social Security8 Armed Force5.5 Charity3.5 Private16.5 Oil1 Others2.5 Treatment CentersNumber Medical Centers47161 Dental Centers8647 Pharmacy Centers6305 Laboratory Sciences950 From The Total Hospital Number Of 1176

6. Members of SHAFAYAB Group Shafayab Gostar Shafayab Farda Shafayab Distributer Modava Saayaan Tadbir Dr. Hamid Khoe Managing director Tehran university professor Member of board of directors at Iran Medical Council Head of Iran Pharmacists’ Scientific Association Former head of Tehran University chain of Pharmacies Dr.Sobhanian Hold a PH.D degree in Anticancer drugs from the UK CEO and Managing director of Shafa yab group university lecturer at Azad Pharmacy University in Tehran. Member of board of directors at Pharmacists’ Scientific association Dr.Morteza Azarnoosh Managing director Former Deputy minister of health and head of Iran FDO Former Director of TPICO holding 35% of total Pharma market in Iran. Former Director of Pasteur Institute of Iran Former Director of Alborz Darou Dr. Hamid Salavati Managing director Former commercial deputy of Hejrat Distribution Co Dr.Maysam Karbalaie Managing director former commercial of Safir Co. Head developer of SQOURENT educational platform Senior consulting software Eng. at Hematogenix

7. Shafayab Group Was founded in 2001 Located in Beheshti Ave. Tehran Top ranking importer of ethical / OTC pharmaceuticals and health care products Represent 15 internationally well-known pharmaceutical companies Was founded in 1999 Drugs and Druggists' Sundries Merchant Wholesalers Emergency importation Was founded in 2006 One of top ten pharmaceutical distributer of Iran Having agency in 20 cities to guarantee prompt and continuous supply Was founded in 1962 located around 80 km west of Tehran total area of the site is 10,000 m2 holds 45 production licenses Around 90 employees currently has an agreement with Novartis, Boehringer and Actavis Was founded in 2015 Representative of dental products in Iran our elite group is collected from well-known Iranian companies Shafayab Gostar Shafayab Farda Shafayab Distributer Modava Saayaan Tadbir

8. Shafayab Gostar Agencies

9. Competition Manufacturer Market Share

10. Most Selling 3M’s Product In Iran

11. STRENGTH /OPPORTUNITY  THIS SUPERIORITY HAS BEEN REINFORCED VIA  HIGH EDUCATED AND UP-TO-DATE MANAGEMENT AND ENGINEERS THAT WORK BY TOGETHER TO GAIN THE COMPANY TARGET.  WORKING WITH HIGH QUALITY PRODUCT,  WELL KNOWN COMPANIES,  LOYALTY CLIENTS AND DOCTORS THAT TRUSTED TO OUR COMPANY AND MADE A DEAL WITH US BEFORE.  SUPPORTIVE RELATION WITH MOH AND SOCIAL SECURITY ORG.  DIFFERENT TALENTED MEMBERS OF SALES TEAMS  SALES AND ADVERTISING GROUP TO MAKE UNIQUE ADVERTISEMENT THUS, HIGH PRODUCTIVE OVERSEA COMPANIES TRUSTED, PREFER AND MAKE A DEAL WITH OUR COMPANY AS EXCLUSIVE AGENT

12. VISION  INVEST IN DIFFERENT LINES UNDER LICENSE MANUFACTURING  NEGOTIATE WITH PRINCIPLES AND SECURE EXPORT OF INTERNATIONAL PRODUCTS  IMPORT DIFFERENT LINES OF DENTIST PRODUCT TO MEET ALL THEIR MAIN REQUIREMENT  AT LEAST ONE OF OUR SOLD PRODUCT SHOULD BE AT ANY CLINIQUE OR HOSPITALS  OUR COMPANY HAS ABILITIES FOR SUPPLIED AND MANAGE IMPORTANT AREA SO WE ARE GOING TO COVER ALL MIDDLE EAST COUNTRIES